title: Mcl-1 inhibitors: a patent review.
abstract: The myeloid cell leukemia-1 (MCL-1) protein is one of the key anti-apoptotic members of the B-cell lymphoma-2 (BCL-2) protein family. Over-expression of MCL-1 has been closely related to tumor progression as well as to resistance, not only to traditional chemotherapies but also to targeted therapeutics including BCL-2 inhibitors such as ABT-263. Therefore, there has been extensive research and development in the last decade in both academic and industrial settings to address this unmet medical need. Areas covered: This review covers the research and patent literature of the past 10 years in the field of discovery and development of small-molecule inhibitors of the MCL-1 anti-apoptotic protein. Expert opinion: Small-molecule strategies to disrupt the protein-protein interactions between MCL-1 and its pro-apoptotic counterparts, such as BAK and BIM, have recently emerged. Several small-molecules based on different scaffolds describe promising in vitro data as MCL-1 selective inhibitors. While many lead compounds remain at the in vitro preclinical development stage, the two most recent patent applications describe promising in vivo data, and one small molecule inhibitor has recently entered into clinical development. It is such an exciting moment that the long awaited clinical studies will generate some insight into the therapeutic potential of this anti-cancer approach, and possibly facilitate the further development of other early stage inhibitors.
authors.affiliation: a Department of Pharmaceutical Sciences , University of Maryland School of Pharmacy , Baltimore , MD , USA.
authors.forename: Lijia
authors.initials: L
authors.lastname: Chen
authors.affiliation: a Department of Pharmaceutical Sciences , University of Maryland School of Pharmacy , Baltimore , MD , USA.
authors.forename: Steven
authors.initials: S
authors.lastname: Fletcher
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology*; D017209:Apoptosis / Q000187:drug effects; D018450:Disease Progression; D015195:Drug Design; D019008:Drug Resistance, Neoplasm; D006801:Humans; D064549:Myeloid Cell Leukemia Sequence 1 Protein / Q000037:antagonists & inhibitors*; D009369:Neoplasms / Q000188:drug therapy / Q000473:pathology; D010330:Patents as Topic
chemical_list: D000970:Antineoplastic Agents; C579095:MCL1 protein, human; D064549:Myeloid Cell Leukemia Sequence 1 Protein
keywords: Apoptosis; MCL-1 inhibitors; cancer; protein-protein interactions